Welcome to our dedicated page for Lyell Immunopharma news (Ticker: LYEL), a resource for investors and traders seeking the latest updates and insights on Lyell Immunopharma stock.
Lyell Immunopharma reports developments tied to its next-generation chimeric antigen receptor, or CAR T-cell, therapy pipeline for patients with cancer. The company’s recurring updates center on ronde-cel, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate for large B-cell lymphoma, and LYL273, a GCC-targeted CAR T-cell product candidate for metastatic colorectal cancer and other GCC-expressing cancers.
Company news also covers clinical-trial activity, FDA designation updates, manufacturing capabilities at the LyFE Manufacturing Center, quarterly financial results, equity financing activity, licensing transactions, investor-conference participation and executive or governance changes.
Lyell Immunopharma (NASDAQ: LYEL) reported Q2 2024 results and business highlights:
- LYL797 Phase 1 trial showed 40% objective response rate and 60% clinical benefit rate in triple-negative breast cancer at highest dose
- Expanded LYL797 development into four new tumor types
- FDA cleared IND for LYL119, a next-gen ROR1-targeted CAR T-cell therapy
- $491.1 million in cash and equivalents as of June 30, 2024
- Net loss of $45.8 million for Q2 2024, compared to $63.9 million in Q2 2023
- R&D expenses decreased to $40.3 million from $47.5 million year-over-year
- G&A expenses decreased to $12.3 million from $19.0 million year-over-year
- Cash runway extended into 2027
Lyell Immunopharma has announced initial clinical data from its Phase 1 trial of LYL797, a ROR1-targeted CAR-T cell product enhanced with anti-exhaustion technology. Key findings include a 40% objective response rate (ORR) and a 60% clinical benefit rate (CBR) at the highest dose of 150 million CAR T cells in patients with triple-negative breast cancer (TNBC). The trial demonstrated that LYL797 can proliferate, infiltrate tumors, and kill cancer cells. No dose-limiting toxicities were reported in patients without lung metastases, although treatable pneumonitis was observed in those with lung involvement. Lyell is expanding the trial to include other ROR1+ cancers and has submitted an IND for LYL119, their next-generation product. An investor webcast will be held today at 8:30 am ET.
Lyell Immunopharma, a clinical-stage company specializing in T-cell reprogramming for solid tumor cell therapies, announced participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is scheduled for June 10 at 4:00 pm ET. Senior management will present during this conference, and a live webcast will be accessible through Lyell's investor section on www.lyell.com. A replay will also be made available post-presentation.
Lyell Immunopharma, a clinical-stage T-cell reprogramming company, will participate in the BofA Securities Health Care Conference on May 14, 2024. The company will showcase its diverse pipeline of cell therapies for solid tumors. Investors can access the live webcast on the Company's website.
Lyell Immunopharma, Inc. (Nasdaq: LYEL) reported business highlights for Q1 2024, including strong financial position with $526.3 million in cash and ongoing advancement of diverse cell therapy pipeline. Key updates include initial clinical data expected for LYL797 and LYL845, IND submission for LYL119, and promising nonclinical data presented at AACR Annual Meeting 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.